Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Rights and Obligations, Development Milestone Payment

+ References

No definition available.

+ Details

Name:	zlab_CollaborativeArrangementRightsAndObligationsDevelopmentMilestonePayment
Namespace Prefix:	zlab_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount represents the additional milestone payments.

+ References

No definition available.

+ Details

Name:	zlab_CollaborativeArrangementRightsAndObligationsMaximumAdditionalMilestonePayments
Namespace Prefix:	zlab_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Payment of upfront fees for license agreement.

+ References

No definition available.

+ Details

Name:	zlab_CollaborativeArrangementRightsAndObligationsPaymentOfUpFrontFeesForLicenseAgreement
Namespace Prefix:	zlab_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Rights and Obligations, Sales-Based Milestone Payment

+ References

No definition available.

+ Details

Name:	zlab_CollaborativeArrangementRightsAndObligationsSalesBasedMilestonePayment
Namespace Prefix:	zlab_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Rights and Obligations, Specified Royalty Term

+ References

No definition available.

+ Details

Name:	zlab_CollaborativeArrangementRightsAndObligationsSpecifiedRoyaltyTerm
Namespace Prefix:	zlab_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=zlab_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=zlab_NovocureLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=zlab_DecipheraPharmaceuticalsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=zlab_GurnetPointCapitalAndNovoHoldingsASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=zlab_ArgenxBvMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=zlab_AmgenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=zlab_InnovivaInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=zlab_BMSMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=zlab_RepotrectinibMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=zlab_AdagrasibMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=zlab_XanomelineTrospiumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=zlab_PfizerIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=zlab_OtherCounterpartiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreements (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Specified royalty term		10 years
Research and development expense		$ 265,868	$ 286,408	$ 573,306
Maximum additional milestone payments		2,202,100
GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sales-based milestone payment		12,000		8,000
Maximum additional milestone payments		16,000
Novocure
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum additional milestone payments		68,000
Deciphera
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum additional milestone payments		173,000
Novo Holdings
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum additional milestone payments		$ 40,500
argenx
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of ordinary shares in connection with collaboration and license arrangement (in shares)	5,681,820
Upfront payment	$ 62,300
Amgen
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Specified royalty term		10 years
Maximum additional milestone payments		$ 37,000
Innoviva
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum additional milestone payments		88,600
BMS \| Repotrectinib
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum additional milestone payments		141,000
BMS \| Adagrasib
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum additional milestone payments		263,000
Upfront payment				65,000
Development milestone payment			10,000
BMS \| Xanomeline-Trospium
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum additional milestone payments		142,000
Pfizer
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum additional milestone payments		263,000
Other counterparties
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment		10,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense			4,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Deciphera
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense				5,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Novo Holdings
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense				6,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| argenx
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense				100,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Innoviva
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense		3,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| BMS \| Repotrectinib
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense		$ 5,000		5,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| BMS \| Xanomeline-Trospium
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense			10,000	$ 35,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Pfizer
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense			$ 30,000